Therapy of recalcitrant macular edema in aphakic and/or eyes with with severe iris-lens diaphragm disruption with longterm intravitreal steroid implants such as Iluvien® or Ozurdex®.
Phase 4
Recruiting
- Conditions
- recalcitrant macular edemaH35.8Other specified retinal disorders
- Registration Number
- DRKS00020282
- Lead Sponsor
- Augenklinik des Klnikums der Ludwig-Maximilians-Universität München
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. chronic macular edema
2. postoperative cystoid macular edema (Irvine Gass-Syndrom)
3. History of migrationof an implantats into the anterior chamber or high Risk of migration
4. History of complications after Ozurdex®-Implantation
5. functional worse eye
6. Central retinal thickness of 500µm or more
Exclusion Criteria
Glaucoma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best corrected Visual Acuity (BCVA) after 12, 24 and 36 months postoperatively.
- Secondary Outcome Measures
Name Time Method Reduction of central retinal thickness (SD-OCT)